High-Yield Urology

🚨 @HighYieldUro 2026 Now Available! ✅ 6 new/updated guideline summaries ✅ 15 new RCTs ✅ 35 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology highyieldurology.com

Best of luck to all those heading to Raleigh to take down the @ABUrology Oral Boards this week!

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

🚨 @HighYieldUro 2026 Now Available! ✅ 6 new/updated guideline summaries ✅ 15 new RCTs ✅ 35 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology highyieldurology.com

JUST IN: @US_FDA approved PARP inh Niraparib +abi/pred for BRCA2-mutated (BRCA2+) metastatic castration-sensitive prostate cancer (CSPC). Data based on AMPLITUDE trial showing rPFS benefit in the overall/BRCA population. Most benefit came from the BRCA2+ tumors: HR 0.46 (vs 0.88). Paper in @NatureMedicine led by @AttardLab @DRathkopf --Approval where therapies work Best! Link: tinyurl.com/rcxaj98

The FDA approval of EV + Pembro in cisplatin ineligible muscle invasive bladder is based on pCR=57% & OS HR of 0.5 vs cystectomy alone. Initial systemic therapy rather than surgery is now preferable for all eligible pts. I suspect this is not the last we hear from EVP in MIBC.

Best of luck to everyone gearing up to ace the @AmerUrological In-Service and @UroOnc OKAT Exams this weekend!

🚨RC48-C016 @NEJM 🇨🇳 484 pts w/ untreated HER2(+) locally advanced or M1 UC ➡️ compared to chemo, combination Tx w/ disitamab (mAb to HER2) - vedotin & toripalimab (PD-1🛑) doubled med PFS (7 vs 13 mos) and med OS (17 vs 32 mos) & ⬇️ G3+ AE’s ✅ nejm.org/doi/full/10.10…

🚨 IMVigor 011 ⁦@NEJM⁩ After cystectomy for MIBC, ctDNA-guided adjuvant Atezolizumab (PD-L1 inhibitor) extended med DFS (10 vs 5 mos) and med OS (33 vs 21 mos) over placebo ✅ nejm.org/doi/full/10.10…

🚨LITESPARK-015 @NEJM 🌎🌍 72 patients w/ advanced, unresectable, and/or metastatic Pheochromocytoma or Paraganglioma ➡️ all got Belzutifan (HIF-2a inhibitor) ➡️ at med f/u 30 mos, obj response rate and disease control were 26% and 85% ➡️ FDA-approved ✅ nejm.org/doi/full/10.10…

🔔 1️⃣ month to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ still time for a boost with @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro ⁦@ABUrology⁩ highyieldurology.com

✌️ months to go!

JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC. -Intravesical form of Gemcitabine - CR: 82.4%/grade ≥3 AE 12.9% - DFS 70.2% at 12m - 51% of CRs with DOR ≥ 12 months.

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche natera.com/company/news/i…

🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology highyieldurology.com

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr @OncoAlert @Annals_Oncology astrazeneca.com/media-centre/p…

I wish I had @HighYieldUro at the start of my residency @brady_urology. It is a great preparation tool for grand rounds and didactics. By adding your own notes in the margins you can tailor it for your own rapid review before In-Service and Boards. highyieldurology.com

JUST IN: @US_FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer! Approval based on ENVISION NCT05243550 trial ! @DanaFarber_GU @AmerUrological